Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of 5% IVIG in Primary Immune Thrombocytopenia (ITP)
NCT07233213Phase 3Recruiting
- Sponsor
- Sichuan Yuanda Shuyang Pharmaceutical
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of intravenous immunoglobulin G in primary immune thrombocytopenia (ITP), sponsored by Sichuan Yuanda Shuyang Pharmaceutical. Started Nov 2025; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07233213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233213.